Sanofi (France) (SAN.PA) Expects FDA Decision on Lemtrada in H2 2013  
1/30/2013 7:46:13 AM

Sanofi expects the U.S. Food and Drug Administration to rule on its application for a new multiple sclerosis treatment called Lemtrada by the second half of this year. The drug, which was developed by Sanofi subsidiary Genzyme, has already been submitted for review by the European Medecines Agency.